Cynomolgus CLEC12A/MICL/CLL-1 protein (Recombinant) (N-His) (STJP020322)
SPECIFICATIONS
HostHEK293 cells
ConjugationUnconjugated
ImmunogenRecombinant Cynomolgus CLEC12A/MICL/CLL-1 Protein is expressed from Expi293 with His tag at the N-terminal.；It contains His65-Ala265.
General Information
| Short Description | Recombinant-Cynomolgus CLEC12A/MICL/CLL-1-N-His protein was developed in hek293 cells using the region His65-Ala265. For use in research applications. |
| Host | HEK293 cells |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Conjugation | Unconjugated |
| Storage Instruction | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Determination Method | < 1 EU/Mu g of the protein by LAL method. |
Target Information
| Immunogen | Recombinant Cynomolgus CLEC12A/MICL/CLL-1 Protein is expressed from Expi293 with His tag at the N-terminal.；It contains His65-Ala265. |
| Immunogen Region | His65-Ala265 |
Additional Info
| Background | CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. |
Information sourced from Uniprot.org